TRVI

Current Thesis

Post-offering digestion setup into a mid-2026 binary. On 2026-04-16/17 Trevi priced a $150M secondary (11.6M shares at $13.00) to fund Haduvio (nalbuphine ER), triggering a gap-down on 2026-04-17. Deal overhang is now known; the $13 print is the line in the sand into Phase 2b RIVER (chronic cough in IPF) topline guided for mid-2026. No clean long setup yet — DORMANT until base-building above $13 on declining volume confirms supply cleared. This is an archetype-5 binary in a MATURING rare-disease-approvals theme; sizing stays small even if it triggers.

Bull Case

• 2026-04-16/17: $150M raise at $13.00 fully funds Haduvio through the RIVER Phase 2b readout — the dilution overhang that capped the tape pre-deal is now priced in.
• Haduvio Phase 2a CORAL (2024 readout) showed statistically significant reduction in 24-hour cough frequency vs placebo in IPF cough — RIVER is a scaled confirmation of a validated mechanism, not a de-novo biology bet.
• Competitive void: Merck's gefapixant (P2X3) received a CRL in 2024; there is NO approved therapy for chronic cough in IPF, making nalbuphine's opioid-sparing kappa-agonist/mu-antagonist profile the de facto front-runner.
• Offering was absorbed by a named syndicate at a single clearing price — no "mystery seller" tail risk; post-deal flow is mechanical, not fundamental.
• Rare-disease-approvals theme still MATURING (not yet SATURATED): peers CRNX, PRAX, VKTX continue to trade premium multiples on pipeline optionality — TRVI re-rates with them if RIVER delivers.

Bear Case

• 2026-04-17 pre-market gap confirmed re-pricing; any daily close below $13.00 means deal buyers are underwater and the path of least resistance is supply bleed for 2–4 weeks.
• Single-asset company: Haduvio IS the pipeline. RIVER miss = 60–80% drawdown scenario (standard small-cap biotech binary math).
• 11.6M new shares ≈ 12–14% dilution; syndicate flipping and index-rebalance lag typically caps upside through the first earnings print post-deal.
• Rare-disease theme MATURING, not ACCELERATING — sell-side has already rotated from generalist biotech buyers to specialist funds; marginal buyer thinner than Q3 2025.
• Chronic cough readouts are notoriously noisy (placebo response rates run 20–40%) — even a "win" on primary endpoint can be re-graded if subgroup data is messy.

Setup & Price Structure

• Offering anchor: $13.00 (2026-04-17 print). This is the entire technical frame.
• 2026-04-17 pre-market gap lower on elevated turnover; flagged across 3 pre-market movers lists indicating dispersed retail attention (not concentrated squeeze setup).
• Key trigger levels:
• Bull trigger: 3 consecutive daily closes ≥ $13.50 on declining volume = supply absorbed, initiate starter.
• Watch level: [entry redacted] must hold on closing basis — losing it flips the setup.
• Bear trigger: a daily close below the thesis-invalidation level = deal anchor broken, demote from active watch.
• No 20-EMA/50-EMA reference yet post-deal — technicals need 5–10 sessions of true price discovery before MA frames mean anything.
• Status as of 2026-04-20: T+3 from offering, still in syndicate stabilization window. Too early to trade either direction — DORMANT.

Catalyst Calendar (next 30 days)

• 2026-04-20 → 2026-04-24: Offering settlement tail (T+1/T+2 from pricing) and initial syndicate stabilization flow. Watch for closing-bid support at $13.00.
• ~2026-05-08 (est.): Q1 2026 earnings — Trevi reported Q1 2025 on 2025-05-08, expect similar cadence. Focus on: cash runway post-raise (target: into H2 2027), RIVER enrollment completion timeline, any pull-forward of topline guidance.
• Mid-2026 (guided, outside 30d window but dominant forward anchor): Phase 2b RIVER topline in chronic cough in IPF — this is THE binary. Every tape move is discounting this.
• No PDUFA in window — Haduvio is pre-approval, RIVER is Phase 2b.

What Would Change Our Mind

• Bullish flip (initiate LOW probe, 1–1.5% sizing): TRVI closes ≥ $13.50 for 3 consecutive sessions on declining volume AND Q1 print (~2026-05-08) confirms runway past RIVER readout with no enrollment slippage.
• Upgrade to MEDIUM: Positive interim DSMB readout or timeline pull-forward for RIVER disclosed via 8-K.
• Bearish confirm (remove from active watch): a daily close below the thesis-invalidation level (roughly 8% below offering) — deal anchor broken, demote to DEAD.
• Thesis-killer (avoid / exit regardless of price): Any 8-K disclosing RIVER enrollment delay, protocol amendment, SAE cluster, or gefapixant FDA resubmission acceptance. Cap-raise follow-on within 90 days = capital-structure red flag, skip permanently.
• Earnings blackout: No new position in the 3 trading days before ~2026-05-08 print.

Correlation Notes

• CRNX (Crinetics) — rare-disease/endocrine readout-to-approval peer; trades as reference multiple for de-risked single-asset biotech.
• PRAX (Praxis Precision Medicines) — small-cap CNS/neuro with similar offering-into-catalyst pattern; mechanically correlated on "biotech binary" risk-on/off days.
• VKTX (Viking Therapeutics) — broader small-cap-biotech beta proxy; moves 1:1 with XBI on sector days.
• XBI — the dominant factor. TRVI's idiosyncratic thesis only expresses cleanly when XBI is flat-to-up; in XBI drawdowns a6-style, deal digestion gets compounded.
• MRK (Merck) — gefapixant owner; any competitive resubmission news is a direct negative catalyst for Haduvio's competitive moat.